KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetShares Repurchased
Ratios

Halozyme Therapeutics (HALO) Receivables - Other (2018 - 2024)

Halozyme Therapeutics (HALO) has disclosed Receivables - Other for 7 consecutive years, with $20.3 million as the latest value for Q4 2024.

  • On a quarterly basis, Receivables - Other rose 1930.0% to $20.3 million in Q4 2024 year-over-year; TTM through Dec 2024 was $20.3 million, a 1930.0% increase, with the full-year FY2024 number at $20.3 million, up 1930.0% from a year prior.
  • Receivables - Other was $20.3 million for Q4 2024 at Halozyme Therapeutics, up from $1.0 million in the prior quarter.
  • In the past five years, Receivables - Other ranged from a high of $69.2 million in Q3 2022 to a low of $243000.0 in Q2 2023.
  • A 5-year average of $21.5 million and a median of $20.1 million in 2022 define the central range for Receivables - Other.
  • Peak YoY movement for Receivables - Other: plummeted 98.78% in 2023, then skyrocketed 1930.0% in 2024.
  • Halozyme Therapeutics' Receivables - Other stood at $7.0 million in 2020, then soared by 328.57% to $30.0 million in 2021, then soared by 130.67% to $69.2 million in 2022, then tumbled by 98.55% to $1.0 million in 2023, then surged by 1930.0% to $20.3 million in 2024.
  • Per Business Quant, the three most recent readings for HALO's Receivables - Other are $20.3 million (Q4 2024), $1.0 million (Q4 2023), and $3.3 million (Q3 2023).